




Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARGS

Last Trade:	2.11
Trade Time:	11:13 AM ET Jan 22, 2018
Change:	-0.06  (-2.959%)
Day Range	2.00 - 2.29
52-Week Range	2.00 - 106.00
Volume	231,183

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 18, 2018*
[Argos Announces One-for-Twenty Reverse Stock Split](#)
- Jan 8, 2018*
[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)
- Nov 28, 2017*
[Argos Provides Financial Update](#)
- Nov 11, 2017*
[Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting](#)
- Nov 9, 2017*
[Argos Reports Third Quarter 2017 Financial Results and Operational Highlights](#)

Financials [\[View all \]](#)

- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Jul 6, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)